Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat...

Detaylı Bibliyografya
Asıl Yazarlar:	Peyrin-Biroulet, L, Sandborn, W, Sands, B, Reinisch, W, Bemelman, W, Bryant, R, D'Haens, G, Dotan, I, Dubinsky, M, Feagan, B, Fiorino, G, Gearry, R, Krishnareddy, S, Lakatos, P, Loftus, E, Marteau, P, Munkholm, P, Murdoch, T, Ordás, I, Panaccione, R, Riddell, R, Ruel, J, Rubin, D, Samaan, M, Siegel, C, Silverberg, MS, Stoker, J, Schreiber, S, Travis, S, Van Assche, G, Danese, S, Panes, J, Bouguen, G, O'Donnell, S, Pariente, B, Winer, S, Hanauer, S, Colombel, J
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Nature Publishing Group 2015

Benzer Materyaller

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
Yazar:: Sandborn, W, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
Yazar:: Peyrin-Biroulet, L, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
Yazar:: Danese, S, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Development of an index to define overall disease severity in IBD
Yazar:: Siegel, C, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
Yazar:: D'Haens, G, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment
Yazar:: Remo Panaccione, ve diğerleri
Baskı/Yayın Bilgisi: (2015-12-01)

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
Yazar:: Jairath, V, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Development of the Crohn's disease digestive damage score, the Lemann score.
Yazar:: Pariente, B, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
Yazar:: Reinisch, W, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Evolving concepts in phases I and II drug development for Crohn's Disease
Yazar:: Jairath, V, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Standardizing scoring conventions for Crohn’s disease endoscopy: An international RAND/UCLA appropriateness study
Yazar:: Khanna, R, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Biosimilars in IBD: hope or expectation?
Yazar:: Gecse, K, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
Yazar:: Vuitton, L, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
Yazar:: Clark, M, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
Yazar:: Gasche, C, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Reliability and initial validation of the ulcerative colitis endoscopic index of severity.
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
Yazar:: Panaccione, R, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Review article: defining remission in ulcerative colitis.
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

European evidence-based Consensus on the management of ulcerative colitis: Current management.
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
Yazar:: Laurent Peyrin-Biroulet, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
Yazar:: Sandborn, W, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Yazar:: Colombel, J, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease
Yazar:: Ma, C, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
Yazar:: D'Haens, G, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
Yazar:: Van Assche, G, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Budesonide MMX® for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis.
Yazar:: Lichtenstein, G, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid
Yazar:: D'Haens, G, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
Yazar:: Yzet, C, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
Yazar:: Gottlieb, K, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

The real-world global use of patient-reported outcomes for the care of patients with inflammatory bowel disease
Yazar:: Horrigan, JM, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Benzimidazoles promote anti-TNF mediated induction of regulatory macrophages and enhance therapeutic efficacy in a murine model
Yazar:: Wildenberg, M, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Antieosinophil Therapeutics
Yazar:: Straumann, A, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis
Yazar:: Samaan, MA, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)